-transparent.png){kind=logo}
The half lives of acetanilide and isoniazid ("model" substrates for oxidation and acetylation respectively) were measured in populations of young (aged 20-35 years) and elderly (aged over 65 years) people. Whereas acetanilide half lives were significantly longer in the elderly, isoniazid half lives were distributed similarly in both populations. The results suggest that liver function does not decline uniformly with age and that heterozygotes for acetylation do not possess survival advantages during their middle years of life.
Related Publications
F Farah, and
W Taylor, and
M D Rawlins, and
O James
June 1992,
Die Pharmazie,
F Farah, and
W Taylor, and
M D Rawlins, and
O James
October 1976,
Clinical pharmacology and therapeutics,
F Farah, and
W Taylor, and
M D Rawlins, and
O James
January 1988,
Pharmacology,
F Farah, and
W Taylor, and
M D Rawlins, and
O James
December 1987,
Schweizerische medizinische Wochenschrift,
F Farah, and
W Taylor, and
M D Rawlins, and
O James
July 1971,
Annals of the New York Academy of Sciences,
F Farah, and
W Taylor, and
M D Rawlins, and
O James
January 1981,
Acta anthropogenetica,
F Farah, and
W Taylor, and
M D Rawlins, and
O James
October 1983,
British journal of clinical pharmacology,
F Farah, and
W Taylor, and
M D Rawlins, and
O James
December 1986,
Toxicology,
F Farah, and
W Taylor, and
M D Rawlins, and
O James
June 1968,
Science (New York, N.Y.),
F Farah, and
W Taylor, and
M D Rawlins, and
O James
November 1990,
Clinical pharmacokinetics,
